Flash e-reader

 Go to e-reader chapter








Table 5.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1999 to 2008

Recipients with Kidney Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 12,765 13,620 14,276 14,779 15,137 16,006 16,483 17,095 16,634 16,521
Tx with Antirejection Treatments 2,441 2,377 2,389 2,177 1,970 1,862 1,701 1,581 1,339 1,026
Antibodies Any in Category 37.1% 35.7% 37.7% 38.7% 48.8% 48.0% 39.3% 45.2% 47.1% 41.0%
Atgam/NRATG/NRATS 6.0% 2.9% 2.5% 2.3% 1.8% 1.1% 1.4% 1.5% 1.0% 1.6%
OKT3 18.7% 14.7% 11.8% 10.7% 9.0% 7.7% 5.5% 4.4% 3.0% 2.4%
Thymoglobulin 7.9% 13.0% 18.1% 23.7% 32.0% 33.0% 28.1% 33.6% 37.0% 32.7%
Zenapax 5.8% 3.4% 2.9% 1.9% 3.1% 3.3% 0.7% 1.6% 1.9% 0.6%
Simulect 1.6% 4.0% 5.0% 3.4% 5.6% 4.8% 4.2% 5.1% 5.5% 5.0%
Campath 0.0% 0.0% 0.0% 0.2% 1.4% 1.5% 1.8% 0.7% 1.0% 0.6%
Corticosteroids Any in Category 78.5% 80.1% 80.2% 79.7% 71.8% 70.6% 75.5% 73.4% 75.0% 71.2%
Steroids 78.5% 80.1% 80.2% 79.7% 71.8% 70.6% 75.5% 73.4% 75.0% 71.2%
Antimetabolites Any in Category 0.1% 0.3% 0.2% 0.1% 0.2% 0.5% 0.2% 0.1% 0.1% 0.1%
Cytoxan 0.1% 0.3% 0.1% 0.1% 0.2% 0.4% 0.2% 0.1% 0.1% 0.1%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.